• Explore /
  • Poster
  • / Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.

Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.

Abstract Poster

Authors

Jaume Capdevila

Jaume Capdevila

Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Jaume Capdevila , Monica Guillot , Montse Pampols , Mercedes Martínez Villacampa , Ismael Macías , Ignacio García Escobar , David Paez , Eduardo Polo , Jorge Aparicio , Ana Ruiz Casado , Gemma Soler , Carmen Castañon , Alejandro García-Alvarez , Maria Jose Safont , Jorge Hernando , Juana Maria Cano , Begoña Navalpotro , David Armario , Guillermo Villacampa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Anal Cancer

Clinical Trial Registration Number

NCT05661188

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS3624)

DOI

10.1200/JCO.2023.41.16_suppl.TPS3624

Abstract #

TPS3624

Poster Bd #

324a

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

PDL1 expression predicts therapeutic outcome in non metastatic anal squamous cell carcinoma (NMASCC).

PDL1 expression predicts therapeutic outcome in non metastatic anal squamous cell carcinoma (NMASCC).

First Author: Ilma Soledad Iseas

First Author: Cathy Eng

First Author: Stefano Kim

First Author: Yuming Zhu